The Role of Human Neural Stem Cell Secretomes on the Repair of Spinal Cord Injury Post-laminectomy in Rattus norvegicus Through the Analysis of Basso–Beattie–Bresnahan Score Locomotors, Interleukin-10, Matrix Metalloproteinase 9, and Transforming Growth Factor-β

Study Design Experimental animal study. Purpose This study aims to investigate the effects of treatment with human neural stem cell (HNSC) secretomes on subacute spinal cord injury (SCI) post-laminectomy by analyzing interleukin-10 (IL-10), matrix metalloproteinase 9 (MMP9), transforming growth factor-β (TGF-β), and Basso–Beattie–Bresnahan (BBB) score locomotors as expressions of neurological recovery. Overview of Literature In the United States, SCI has a recovery rate of 0.08%, tetraplegia 58.7%, and paraplegia 40.6%. Therapeutic approaches to SCI have focused on modulating the secondary cascade to prevent neurological deterioration and glial scar formation. Increasing evidence has shown that the success of cell-based SCI therapy is attributed to the secretomes rather than the cells themselves, but the effect of treatment with HNSC secretomes in SCI is unclear. Methods This experimental study investigated 15 Rattus norvegicus rats that were divided into three groups: (1) normal, (2) SCI+non-secretome, and (3) SCI+secretome (30 μL, intrathecal Th10). Model subacute SCI post-laminectomy was performed in 60 seconds using an aneurysm Yasargil clip with a closing forceps weighing 65 g (150 kdyn). At 35 days post-injury, the specimens were collected, and the immunohistochemicals of IL-10, MMP9, and TGF-β were analyzed. Motor recovery was evaluated based on the BBB scores. Results The SCI post-laminectomy of rats treated with HNSC secretomes showed improvements in their locomotor recovery based on the BBB scores (p=0.000, mean=18.4) and decreased MMP9 (p=0.015) but had increased the levels of IL-10 (p=0.045) and TGF-β (p=0.01). Conclusions These results indicate that the factors associated with the HNSC secretomes can mitigate their pathophysiological processes of secondary damage after SCI and improve the locomotor functional outcomes in rats.

[1]  Jiang Peng,et al.  Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury , 2022, Stem Cell Research & Therapy.

[2]  J. Dai,et al.  A DAMP-scavenging, IL-10-releasing hydrogel promotes neural regeneration and motor function recovery after spinal cord injury. , 2021, Biomaterials.

[3]  Yoichi M Ito,et al.  Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series , 2021, Clinical Neurology and Neurosurgery.

[4]  B. Fiani,et al.  Current updates on various treatment approaches in the early management of acute spinal cord injury , 2021, Reviews in the Neurosciences.

[5]  Q. H. Looi,et al.  Treatment of spinal cord injury with mesenchymal stem cells , 2020, Cell & bioscience.

[6]  J. Fawcett,et al.  Neurochemical biomarkers in spinal cord injury , 2019, Spinal Cord.

[7]  W. Murphy,et al.  Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury , 2019, Journal of neuroinflammation.

[8]  D. Resnick,et al.  Folic Acid Modulates Matrix Metalloproteinase-9 Expression Following Spinal Cord Injury , 2019, Annals of neurosciences.

[9]  I. H. Dilogo,et al.  Role of Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) in the Bone Regeneration: A Systematic Review from 2007-2018 , 2019, Annual Research & Review in Biology.

[10]  S. Allan,et al.  The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  I. Fournier,et al.  Localized Intrathecal Delivery of Mesenchymal Stromal Cells Conditioned Medium Improves Functional Recovery in a Rat Model of Spinal Cord Injury , 2018, International journal of molecular sciences.

[12]  Julie Swenson,et al.  Select Topics for the Exotic Animal Veterinarian , 2017, Exotic Animal Formulary.

[13]  Brett J. Hilton,et al.  Cell transplantation therapy for spinal cord injury , 2017, Nature Neuroscience.

[14]  Shiying Li,et al.  The Regulatory Effects of Transforming Growth Factor-β on Nerve Regeneration , 2017, Cell transplantation.

[15]  A. Eid,et al.  Inflammogenesis of Secondary Spinal Cord Injury , 2016, Front. Cell. Neurosci..

[16]  M. Mildner,et al.  The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats , 2015, Experimental Neurology.

[17]  A. Didangelos,et al.  Regulation of IL-10 by Chondroitinase ABC Promotes a Distinct Immune Response following Spinal Cord Injury , 2014, The Journal of Neuroscience.

[18]  P. Yip,et al.  Modulating inflammatory cell responses to spinal cord injury: all in good time. , 2014, Journal of neurotrauma.

[19]  V. Lafage,et al.  Spinal cord injury models: a review , 2014, Spinal Cord.

[20]  R. F. de Araújo Júnior,et al.  Azilsartan Increases Levels of IL-10, Down-Regulates MMP-2, MMP-9, RANKL/RANK, Cathepsin K and Up-Regulates OPG in an Experimental Periodontitis Model , 2014, PloS one.

[21]  F. Biering-Sørensen,et al.  Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: Systematic review with meta-analyses of rat models , 2014, Neurobiology of Disease.

[22]  K. Osuka,et al.  Different modifications of phosphorylated Smad3C and Smad3L through TGF-β after spinal cord injury in mice , 2013, Neuroscience Letters.

[23]  D. Basso,et al.  Elevated MMP-9 in the Lumbar Cord Early after Thoracic Spinal Cord Injury Impedes Motor Relearning in Mice , 2013, The Journal of Neuroscience.

[24]  Colton D Thompson,et al.  The therapeutic role of interleukin-10 after spinal cord injury. , 2013, Journal of neurotrauma.

[25]  S. Lakhan,et al.  Matrix Metalloproteinases in Neuropathic Pain and Migraine: Friends, Enemies, and Therapeutic Targets , 2012, Pain research and treatment.

[26]  M. Sogayar,et al.  TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells , 2012, BMC Cancer.

[27]  D. Basso,et al.  A sensitive and reliable locomotor rating scale for open field testing in rats. , 1995, Journal of neurotrauma.